NM
Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
$0.73 -1.48% (-$0.01)
1M -55.21%
Market Cap $139.0M
P/E Ratio -
Div. Yield -
ROE 242.29%
Bulios Fair Price
$0.87
19.2% upside
Current Price
$0.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NMRA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
65 /100
Fair P/B 3.12x
P/FCF N/A
P/S N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 169.86%
ROIC 216.08%
Debt
69 /100
Low Current ratio 4.50x
Int. coverage -32.09x
Debt/Equity 0.01x
Stability
21 /100
Unstable EPS volatility 43.21%
Profitable years 0
Beta 2.74x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NMRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Josh Pinto
Employees
63
Headquarters
Watertown
Upcoming events
05 NOV
Earnings
Upcoming earnings report